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II. Abstract 
Nucleus accumbens dopamine (DA) is an important regulator of locomotion. Recent 
research has also indicated the neuromodulator adenosine has a role in regulating locomotion. 
The adenosine A2A receptor subtype is colocalized with DA D2 receptors on medium spiny 
neurons in the striatum and nucleus accumbens, and interactions between adenosine A2A and 
DA D2 receptor antagonists are significant for regulating various aspects of motor and 
motivational function. The adenosine A2A antagonist MSX-3 has been shown to reverse the 
suppression of locomotion induced by the DA D2 antagonist eticlopride. Recently, the structure 
of MSX-3 was modified to produce the amino acid ester prodrug MSX-4, which is highly water 
soluble, and has high oral bioavailability. The present studies sought to elucidate the interactions 
between DA D2 antagonist eticlopride and the A2A adenosine antagonist MSX-4 by determining 
if MSX-4 could reverse eticlopride-induced locomotion suppression. Moreover, the induction of 
anxiety was measured by recording the relative amount of activity in the inner portion of the 
open field arena. In the current study, rats were injected with eticlopride, MSX-4, saline, or both 
eticlopride and MSX-4. Locomotion was measured by total activity counts in the open field test 
during two 5-minute sessions. To determine if the interactions between eticlopride and MSX-4 
are related to the induction of anxiety, the relative number of activity counts in the inner portion 
of the open field was used as the measure of anxiety. In order to provide a neural marker of the 
interaction between eticlopride and MSX-4, histological studies measured the expression of c-
Fos and DARPP-32 (THR34) immunoreactivity, which are commonly used as a marker of neural 
activity. Eticlopride significantly suppressed locomotion and increased c-Fos and DARPP-32 
expression in the nucleus accumbens as compared to vehicle animals. The A2A antagonist MSX-
4 reversed the locomotion suppression induced by eticlopride, and decreased the eticlopride-
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induced expression of c-Fos and DARRP-32 in the nucleus accumbens. MSX-4 produced no 
significant increase in the anxiety index. These results indicate that the effects of MSX-4 are 
consistent with the general antiparkinsonian profile of adenosine A2A antagonists, and suggest 
that signs of anxiogenesis as measured by the open field were not produced as a side effect of 
this drug. This research may be relevant for the development of novel drug therapies for the 
treatment of parkinsonism and psychomotor dysfunctions in depression. 
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III. Introduction 
Locomotor activity is regulated by complex neurochemical interactions which occur in 
the circuitry of the basal ganglia. Considerable evidence has implicated nucleus accumbens 
dopamine (DA) in the regulation of locomotor activity (Annett et al. 1989, Baldo et al. 2007, 
Duvauchelle et al. 2000, Gong et al. 1999, Hemby et al. 1992, Kelly et al. 1989, Pijenburg et al. 
1973, Pijenburg et al. 1976). Administration of DA antagonists either systemically or directly 
into the nucleus accumbens reduces drug-induced, novelty-induced, food-induced and 
spontaneous locomotion (Ahlenius et al. 1987, Correa et al. 2002, Correa et al. 2000, Kelly et al. 
1976, Koob et al. 1978, McCullough et al. 1992). The death of DA containing neurons leads to 
the hypokinetic disorder Parkinson’s disease in and thus DA is considered particularly important 
in the regulation of movement (Davie 2008).  
Recent research has also indicated that the neuromodulator adenosine interacts with DA 
in the regulation of various behavioral functions, including locomotion (Antoniou et al. 2005, 
Ferre et al. 1997, Fuxe et al. 2003, Fuxe et al. 2007, Hauber et al. 1998, Hauber et al. 1997, 
Ishiwari et al. 2007, Nagel et al. 2003, Stromber et al. 2000, Svenningsson et al. 1999, Barraco et 
al. 1993).  A1 and A2A adenosine receptor subtypes are involved in striatal function. The A1 
receptor is distributed more widely throughout the brain while anatomical studies have shown 
that adenosine A2A receptors have a high level of expression within both the neurostriatum and 
the nucleus accumbens (Svenningsson et al. 1999; Wang et al. 2000; Hettinger et al. 2001;Chen 
et al. 2001, Fastbom et al 1987).  Physiologically, adenosine and DA receptors have been shown 
to overlap in their expression in these regions, and stimulation of adenosine receptors changes 
the binding affinities of DA receptors (Schiffman et al. 1991; Fink et al. 1992; Rosin et al. 1998; 
Svenningsson et al. 1999; Hillion et al. 2002; Chen et al. 2001; Fuxe et al. 2003, 2007; Mingote 
et al. 2008). Adenosine A1 and DA D1 receptors colocalize on substance P striatonigral neurons 
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and the A2A and DA D2 receptor subtypes colocalize on the same enkephalin-positive ventral 
and dorsal striatopallidal neuron (Schiffman et al. 1991; Fink et al. 1992; Rosin et al. 1998; 
Svenningsson et al. 1999; Hillion et al. 2002; Chen et al. 2001; Fuxe et al. 2003, 2007; Mingote 
et al. 2008). Adenosine A2A and DA D2 receptors are thought to form heteromeric complexes 
that influence neurotransmitter binding such that stimulation of A2A receptors decreases the 
affinity of DA D2 receptor agonists (Ferré, 1997; Svenningsson et al. 1999; Ferré et al. 2008).  In 
addition to heteromeric interactions, these receptors also interact through signal transduction 
mechanisms coupled to G-protein-coupled c-AMP second messenger systems (Ferré, 1997; 
Svenningsson et al. 1999; Ferré et al. 2008). 
The relation between adenosine and DA has been of particular interest in recent years due 
to research on Parkinson’s disease. Parkinson’s disease is a neurological disorder associated with 
DA depletions in the basal ganglia, specifically the caudate putamen (Salamone et al. 1998). 
“Parkinsonism” is a term referring to a broad spectrum of motor disorders whose symptoms 
include akinesia (lack of movement), bradykinesia (slowed movement), impairments in motor 
control and locomotion, rigidity and tremor. Parkinsonian symptoms have been produced in rats 
using DA antagonists, the same drugs used as a current treatment for psychosis (Ferre 1997, 
Salamone et al. 1998). Animal models looking at catalepsy, rotation, tremor and locomotion 
have demonstrated that antagonism of adenosine A2A receptors could be an effective therapy for 
parkinsonism (Ferré et al. 2001, Hauber et al. 2001, Ishiwari et al. 2007, Kanda et al. 1998, 
Matsuya et al. 2007, Pinna et al. 2005, Salamone et al. 2007, Salamone et al. 2008, Bara-Jimenez 
et al. 2003, Ferré et al. 2004, Simola et al. 2006, Tronci et al. 2007). Recent research has 
demonstrated the importance of A2A receptor antagonist in the reversal of DA antagonist induced 
locomotor suppression and tremulous movement, which were induced by haloperidol and 
reversed after injections of the adenosine A2A antagonist KF17837 (Correa et al. 2004, Wardas et 
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al. 2001). The interactions between adenosine and dopamine receptor antagonists have 
differential effects depending on their selectivity profile. MSX-3, an adenosine A2A antagonist 
significantly reverses the suppression of locomotion induced by the DA D2 antagonist 
eticlopride; however, the adenosine A1 antagonists DCPCX and CPT were unable to reverse the 
locomotor impairments elicited by eticlopride (Collins et al. 2010b).   
Clearly the antagonistic relationship between adenosine and DA has implications for the 
treatment of parkinsonism. Furthermore, it has been suggested that adenosine A2A receptors 
could be effective at treating psychomotor slowing and anergia in depression and other disorders 
(El Yacoubi et al. 2003; Hanff et al. 2010, Hodgson et al. 2009, Salamone et al. 2007, 2010). A 
number of papers have investigated the ability of adenosine A2A antagonists to reverse the 
locomotor suppression that results from interference of DA transmission. In one particular study, 
locomotor suppression induced by the DA depleting agent reserpine was reversed by the 
administration of the adenosine A2A antagonist KW6002 (Shiozaki et al. 1999). This drug was 
also used to rescue locomotor suppression expressed by DA D2 receptor deficient mice (Aoyama 
et al. 2000). Injections of MSX-3 either systemically or directly into the nucleus accumbens core 
increased locomotor activity in haloperidol-treated rats (Ishiwari et al. 2007). In addition, 
adenosine A2A antagonists have been shown to have psychomotor stimulant properties, and to 
reverse many of the behavioral effects of DA D2 antagonists such as decreases in operant lever 
pressing and effort-related choice behavior (Randall et al. 2011, Font et al. 2008, Mingote et al. 
2008). Based on this preclinical research, it has been suggested that adenosine A2A antagonists 
could be useful as antiparkinsonian drugs, antidepressants, or as a treatment for motivational or 
effort-related symptoms such as psychomotor retardation, anergia, apathy and fatigue, which are 
core symptoms of depression and other psychiatric disorders (Ferré et al. 1997; Svenningsson et 
al. 1999; Wardas et al. 2001; Morelli and Pinna 2001; Hodgson et al. 2009; Salamone et al. 
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2008a,b., El Yacoubi et al. 2003; Hanff et al. 2010, Hodgson et al. 2009, Salamone et al. 2007, 
2010, Marin, 1996; Demyttenaere et al. 2005; Salamone et al. 2006; Friedman, 2009). 
With the growing clinical interest in adenosine A2A antagonists, developing and testing 
novel adenosine A2A antagonists is becoming a primary research priority (Le Witt et al. 2008; 
Pinna 2009; Hodgson et al. 2009; Salamone,2010a). Developing novel ligands that have useful in 
vivo characteristics is an important aspect in drug development (Santerre et al. submitted). Many 
drugs have low absorption properties, or low solubility and blood brain barrier penetrability 
which make them difficult to use clinically (Müller, 2009). Prodrugs are an effective way of 
ameliorating or alleviating some of these absorption issues. Prodrugs are bioreversible 
derivatives of a drug that is administered in its inactive form and is enzymatically transformed to 
its active form (Rautio et al., 2008; Müller, 2009). Prodrugs are developed by attaching an 
inactive promoiety to the pharmacologically active parent drug via a covalent bond that is easily 
altered chemically or enzymatically (Rautio et al., 2008). Ideally, when the prodrug is cleaved it 
will produce a high ratio of the parent drug, and the promoiety will be non-toxic (Rautio et al., 
2008). When the drug and promoeity are cleaved, the pharmacologically active parent drug is 
released and absorbed into the system (Rautio et al., 2008). Essentially, the use of prodrugs 
enhances the clinical relevance of a drug without changing the pharmacological activity of the 
parent drug (Santerre et al. submitted). One example of an adenosine A2A antagonist parent drug 
that has been used in prodrug development is MSX-2. MSX-2 has poor water solubility (Müller, 
2009). One approach to increase water solubility is to attach a promoiety to the drug. MSX-3 was 
produced as a prodrug of MSX-2 (Müller, 2009). As mentioned earlier, previous studies have 
shown that MSX-3 can reverse the behavioral effects of DA D2 antagonists (Collins et al. 2010). 
Recently, a new prodrug of MSX-2 was developed (Vollmann et al. 2008). This new prodrug, 
MSX-4, is much more water soluble than MSX-3. MSX-4 was also found to be stable in artificial 
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gastric acid and readily cleaved by pig liver esterase into MSX-2 suggesting that it could be 
bioavailable (Vollmann et al. 2008). 
Examining the behavioral profile of a novel drug is the next step in drug development. 
Although MSX-3 has been widely used in vivo, the behavioral effects of MSX-4 have not been 
studied. The present study focused on characterizing the behavioral actions of MSX-4 in relation 
to locomotion. However, current research suggests that adenosine is also related to anxiety 
(Correa and Font, 2008, Imaizumi et al. 1994). For example, caffeine, a commonly used 
stimulant, has been shown to induce anxiety in humans and animals (Greden 1974, Uhde et al. 
1984, Bruce 1990).  Recent research has concentrated on the role of adenosine in animal models 
of anxiety. Studies have found that adenosine A1 and A2A receptor subtypes are the most closely 
related to anxiety, and that blocking one or both of these receptors will produce an anxiogenic 
effect in rats (Kulkarni et al. 2007, Jain et al. 1995). Adenosine plays a parallel role in both 
maintaining homeostasis and modulating transmitters at the synaptic level (Cunha 2001). On its 
own, it has been shown that adenosine administration induces anxiolysis (i.e., anxiety-relieving) 
while adenosine antagonism produces anxiogenic effects (i.e., increases in anxiety-relate 
behaviors; refs. Kulkarni et al. 2007, Jain et al. 1995). It was shown that caffeine, a non-selective 
adenosine A1 and A2A antagonist, decreases the time spent in the open arms of the elevated plus 
maze, causing a particular preference for closed sections of the maze (El Yacoubi et al. 2000). It 
is still unknown whether the anxiogenic effect of caffeine is A1 or A2A specific but research has 
indicated that these properties are due to the simultaneous blockade of A1 - A2A receptors (El 
Yacoubi et al. 2000, Fredholm et al. 1999). 
Many of the early behavioral studies looking at the effects of adenosine on anxiety have 
used non-selective adenosine antagonists. Data obtained from pharmacological and genetic 
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research of both selective A1 receptor A2A receptor antagonists have yielded contradictory 
results. Adenosine A1 receptor knock-out mice have normal levels of locomotion but show more 
anxiety than wild-type mice (Johansson et al. 2001, Gimenez-Llort et al. 2001). Research using 
A1 receptor antagonists show that in different studies, the same drug has anxiogenic effects or no 
effect. DPCPX decreased the time spend in the light zone of the dark/light test in mice, and in the 
elevated plus maze (Imaizumi et al. 1994, Prediger et al. 2006). However, in multiple other 
studies, DPCPX had no effect on the anxiety-like behaviors of mice in the elevated plus maze, 
dark/light box, or open field arena (El Yacoubi et al. 2000, Griebel et al. 1991, Jain et al. 1995, 
Prediger et al. 2006). Several limited studies of selective adenosine A1 agonists have suggested 
that A1 agonists seem to produce anxiolysis. The selective adenosine A1 receptor agonist CPA 
decreased anxiety-like behaviors in the elevated plus maze (Jain et al. 1995). CCPA, an analogue 
of CPA has also shown anxiolytic effects in the plus maze and the dark/light test (Prediger et al. 
2004, Florio et al. 1998, Prediger et al. 2006). From this previous research it is clear those 
adenosine A1 antagonists do not show a clear pattern of effects on anxiety; however A1 agonists 
seem to be mostly anxiolytic. 
Due to the concentration of A2A receptors in the striatum, it has been suggested that the 
involvement of adenosine in anxiety is mainly due to A1 activation (Jain et al. 1995). 
Nonetheless, A2A receptors are also present in the extended amygdala and hypothalamus which 
are brain regions involved in the regulation of anxiety and stress responses (Moreau et al. 1999). 
In addition, genetic studies in humans suggest that a polymorphism in the A2A receptor gene may 
render susceptibility to the development of panic disorder (Deckert et al. 1997). Pharmacological 
data in animals, like the A1 data, does not point to a clear involvement of A2A receptor in the 
regulation of anxiety. DMPX, an adenosine A2A receptor antagonist did not have a significant 
effect on anxiety-like behavior in an elevated plus maze, open field, or Vogel conflict test in rats 
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(Jain et al. 1995, Thorsell et al. 2007). However, in genetic animal studies, A2A receptor knock-
out mice display more anxiety and reduced locomotion than wild-type mice (Yacoubi et al. 2000, 
Ledent et al. 1997). This is consistent with the knowledge that adenosine A2A receptors seem to 
regulate propiomelanocortin (POMC) gene expression (Jegou et al. 2003). Increased POMC 
expression leads to hyperactivity of the pituitary-adrenocortical axis than in wild-type mice 
(Jegou et al. 2003). In light of the research relating adenosine to anxiety, it is important to look 
for side effects when testing a novel drug. Returning to the original discussion, if the adenosine 
A2A antagonist MSX-4 induces anxiety that is too severe, it may outweigh the benefits of using 
MSX-4 as a potential treatment for disorders such as Parkinsonism, psychomotor slowing, and 
depression.  
In order to study the neurochemical interactions between dopamine and adenosine as they 
relate to locomotion and anxiety, several behavioral assays have been developed. The typical 
paradigms used to measure locomotion include locomotion chambers and the open field arena 
which look at overall rodent movement. For anxiety-like behaviors, tests such as the open field, 
the elevated plus maze and the light/dark box have been most commonly used in the laboratory.. 
While many of these paradigms test either locomotion or anxiety, the open field arena can 
actually test both behaviors. 
 The open field arena consists of a square base that is surrounded by four tall walls (Figure 
5).  The base is divided into a five by five grid. A lamp emitting red light is placed above the 
center of the arena. The animal is placed in the middle of the arena and is allowed to move 
around for a ten minute session. Two experimenters observe the session and tally the number of 
inner and outer crossings that the animal makes. Crossings were defined as the movement of 
both front paws from one square to another. Outer crossings were defined as movement into one 
of the squares adjacent to the walls, while inner crossings were defined as movement into one of 
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the central squares. The total activity of the animal can be calculated by adding the number of 
inner crossings with the number of outer crossings.  
In terms of measuring anxiety-like behavior, it is well known that rodents prefer small 
dark spaces as opposed to bright open ones (Montgomery 1958). In the open field, the areas near 
the wall, or the outer edged of the arena, are darker and more closed off than the arena in the 
center of the arena. Animals which explore more around the outer edged of the arena are 
considered to show higher anxiety-like behaviors than animals which explore in the inner part of 
the arena (Prut and Belzung, 2003). This model for anxiety has been validated using the 
benzodiazepine inverse agonist FG7142 which was shown to increase the time spent in the outer 
edges of the open field (Sink et al. 2010). 
The present study sought to elucidate the interactions between DA D2 antagonist 
eticlopride and the A2A adenosine antagonist MSX-4 by determining if MSX-4 could reverse 
eticlopride-induced locomotion suppression. Moreover, the induction of anxiety was measured 
by recording the relative amount of activity in the inner portion of the open field arena. To 
provide a cellular marker of the interaction between eticlopride and MSX-4, a second study to 
study the immunoreactivity of two markers of signal transduction, c-Fos and DARPP-32 
(Thr34), was determined in brain sections of nucleus accumbens. It was hypothesized that MSX-
4 would show similar behavioral and neurochemical characteristics as the adenosine A2A 
antagonist MSX-3, by reversing the suppression of locomotion induced by eticlopride and 
attenuate eticlopride-induced increases in c-Fos and DARPP-32 expression. 
 
IV. Materials & Methods 
Animals 
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     A total of 29 adult male Sprague-Dawley rats  (Harlan Sprague Dawley, Indianapolis, IN, 
USA) with no prior drug experience and minimum handling were paired-housed in a colony 
maintained at 23oC, with a 12 hour light/dark cycle. The rats weighed between 300-390 grams at 
the beginning of the experiment and had ad libitum access to lab chow and water. These studies 
were conducted according to University of Connecticut and NIH guidelines for animal care and 
use. 
Drugs and Dose Selection 
     This study used intraperitoneal (IP) injections of eticlopride (Sigma) and MSX-4 (Muller 
laboratory).  Eticlopride (S(-)-3-chloro-5-ethyl-N-[(ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-
methoxybenzamide HCL), a D2 antagonist, was dissolved in 0.9% saline and injected at a dose 
of 0.08mg/kg. MSX-4 (L-valine-3-{8-[(E)-2-[3-methoxyphenyl)ethenyl]-7-methyl-1- 
propargylxanthine-3-yl}propyl ester hydrochloride), the A2A antagonist prodrug that is converted 
into MSX-2 in vivo, was dissolved deionized H2O, and injected at a dose of 8.0 mg/kg. 
Behavioral Procedures 
Open Field Maze: The open field consisted of a Plexiglas-covered black floor  (115×115 cm) 
with red lines spaced 23 cm apart, dividing the floor into a five-by-five grid. Walls around the 
perimeter measured 44 cm in height (Figure 5). Testing was performed in a very dimly lit room 
with a single red light situated above the center of the box. The apparatus was novel to the 
subject at the time of testing, and each subject was tested only once. Two experimenters who 
were blind to the treatment condition observed the session, and tallied the number of inner and 
outer line crossings. Crossings were defined as movement of both front paws from one square to 
another. Outer crossings were defined as movement into one of the squares adjacent to the walls, 
while inner crossings were defined as movement into one of the central squares. Each 10-min 
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session was divided into two 5-min bins. Testing was conducted during the light part of the 
light–dark cycle. 
c-Fos and pDARPP-32 (THR34) Immunohistochemistry 
Animals were anesthetized with CO2 and perfused with physiological saline followed by 
formalin ninety min after IP injection. The brains were stored in formalin and then were 
cryoprotected for two days before being sliced into 50-µm sections using a cryostat and stored in 
wells containing Dulbecco's phosphate buffered saline (PBS). Sections for c-Fos visualization 
were incubated in 0.3% hydrogen peroxide (H202) for 30 min to block endogenous staining and 
sections for DARPP-32 visualization were incubated in a solution of 0.1% triton-X, 5% normal 
donkey serum, and PBS for 30 min to block endogenous staining. c-Fos sections were incubated 
in the primary antibody, anti-c-Fos (1:5000, Calbiochem, Germany), and DARPP32 sections 
were transferred into the primary antibody anti-pDARPP32 at a concentration of 1:1000 (Santa 
Cruz Biotechnology, USA) at 4 °C for 24 h. Subsequently, the sections were incubated in the 
secondary antibody, anti-rabbit horseradish peroxidase conjugate, Envision Plus (DAKO, 
Denmark) for 1.5 h. The visualization of c-Fos  and DARPP-32 expression was completed using 
the chromagen diaminobenzidine (DAB). Tissue from the different treatment groups was 
processed together in batches in order to control for variability in the immunohistochemical 
reaction. Cover-slipped slides were examined microscopically to determine and digitally capture 
marked cells in the regions of interest. The sections were photographed using a Nikon Eclipse 
E600 (Melville, NY, USA) upright microscope equipped with an Insight Spot digital camera 
(Diagnostic Instruments, Inc). Images of the region of interest (nucleus accumbens core) were 
magnified at 20x and captured digitally using SPOT software. Cells that were positively labeled 
for c-Fos or DARPP-32 were quantified with ImageJ software (v.1.42, National Institutes of 
Kovner, R 16 
 
Health sponsored image analysis program) and a macro written to automate particle counting 
within the region of interest. The size of the region of interest counted was 1000x1000µm. For 
each animal, cell counts were at levels that correspond to 1.70 mm through 0.70 mm relative to 
bregma (Paxinos and Watson, 1997) bilaterally from at least three sections, and counts were 
averaged across sides and sections. 
Experiment 1: Ability of MSX-4 to reverse the effects of eticlopride in the open field. 
Naïve rats (total n=29; 7-8 per group) received one of the following treatments: saline vehicle IP 
(30 min before testing) plus deionized water vehicle IP (40 min before testing), 0.08 mg/kg 
eticlopride IP (30 min before testing) plus deionized water vehicle IP (40 min before testing), 
0.08 mg/kg eticlopride IP (30 min) plus 8.0 mg/kg MSX-4 IP (40 min), or saline vehicle IP (30 
12 min) plus 8.0 mg/kg MSX-4 IP (40 min). Rats were then tested in the open field as described 
above, and were assessed for both total locomotor activity and relative inner activity. 
 
Experiment 2: Ability of MSX-4 to reverse the effects of eticlopride on c-Fos and DARPP-32 
immunoreactivity in nucleus accumbens neurons. Experimentally naïve rats (n=24; 6 per group) 
were randomly assigned to the following IP treatments: 0.9% saline vehicle plus deionized water 
vehicle, 0.08 mg/kg eticlopride plus deionized water vehicle, 0.08 mg/kg eticlopride plus 8.0 
mg/kg MSX-4, or saline vehicle plus 8.0 mg/kg MSX-4. All animals were anesthetized with CO2 
and perfused 90 min after both injections with physiological saline followed by 3.7%  
formaldehyde; brains were removed and stored at 4 °C in formaldehyde for one day, and then 
were put in 0.9% sucrose. 
 
V. Results 
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In experiment 1, there was an overall significant effect of drug treatment on total locomotor 
activity (Figure 1; F (3,22) = 5.6, p < 0.005). Planned comparisons showed that eticlopride 
produced a significant reduction in locomotion relative to vehicle control (p < 0.05). In addition, 
co-administration of 8.0 mg/kg MSX-4 with eticlopride produced a significant increase in 
locomotor activity compared to eticlopride plus vehicle (p < 0.05). However, there were no 
significant effects of drug treatment on relative inner activity (Figure 2; F (3,22) = 0.88, n.s.), 
which is used as a marker of anxiety-related effects of drugs. 
The results of experiment 2 are shown in Figures 3 and 4. There was an overall effect of 
drug treatment on the number of c-Fos positive cells (Figure 3; F (3,20) = 34.1, p < 0.001). 
Planned comparisons showed that eticlopride increased c-Fos positive cell counts relative to 
vehicle alone (p < 0.05), and that the combination of MSX-4 plus eticlopride significantly 
reduced the number of c-Fos positive cells as compared with eticlopride alone (p < 0.05). There 
also was an overall effect of drug treatment on the number of DARPP-32 positive cells (Figure 4; 
F (3,20) = 27.8, p < 0.001).  Planned comparisons showed that eticlopride increased DARPP-32 
positive cell counts relative to vehicle alone (p < 0.05), and that the combination of MSX-4 plus 
eticlopride significantly decreased DARPP-32 positive cells as compared with eticlopride alone 
(p < 0.05).  
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VI. Discussion  
The present study was conducted to determine the ability of the novel adenosine A2A 
antagonist prodrug MSX-4 to reverse the locomotor suppression induced by the D2 antagonist 
eticlopride.  This study also looked at the ability of MSX-4 to attenuate the signal transduction 
effects of eticlopride-induced expression of c-Fos and DARPP-32 in the nucleus accumbens. 
MSX-4 significantly attenuated the suppression of open field locomotion induced by eticlopride. 
This is consistent with previous studies showing that adenosine A2A antagonists such as MSX-3, 
KF 17837, and KW 6002 could reverse the suppression of locomotion induced by D2 antagonists 
in the open field and small stabilimeter cages (Correa et al. 2004, Ishiwari et al. 2007; Salamone 
et al. 2008a; Collins et al. 2010, 2012). MSX-4 had no effect on locomotion when administered 
alone, which is consistent with previous research showing that KF 17837 did not increase 
locomotor activity when administered alone (Correa et al. 2004).  It is possible that a higher dose 
of MSX-4 would have increased open field activity, or that a different test, such as a low 
response rate operant schedule, would be more sensitive to the stimulant effects of MSX-4 
(Randall et al. 2011).  
MSX-4 did not induce anxiety-like behavior in the open field. MSX-4 had no significant 
effect on relative inner activity in the open field, which is considered an indicator of anxiogenic 
behavior. Rodents that spend less time exploring the inner portion of the arena are considered to 
have higher levels of anxiety (Prut and Belzung, 2003). As explained at the beginning, it is 
important to examine the effects of adenosine A2A antagonists on measures of anxiety, like the 
open field, because of their potential anxiogenic effects (Correa and Font, 2008). These 
anxiogenic side-effects would be highly undesirable if MSX-4 is used clinically. Future research 
should assess the effects of MSX-4 using other anxiety-related tasks such as the elevated plus 
maze. Nonetheless, the involvement of adenosine in anxiety is still in question. Interactions of 
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adenosine with other neurotransmitter systems, basal levels of adenosine, and baseline levels of 
anxiety-like behavior all have an effect on the anxiety-like behaviors exhibited (Correa and Font, 
2008). Future animal studies looking at the effects of adenosine on anxiety should consider 
looking at rodent models of behavior inhibition (Qi et al. 2010) and anxiety to see if 
concentrations of basal adenosine differ for animals that show high and low levels of anxiety and 
stress. In addition, it would be interesting to determine if differing baseline levels of anxiety is 
reflective of expression of A1 and A2A receptors in the extended amygdala and other regions 
related to anxiety and stress response. 
Immunohistochemistry for c-Fos and DARPP-32 were used to provide neural markers of 
the ability of MSX-4 to reverse the cellular actions of eticlopride. In the present study, MSX-4 
reversed the increase in both c-Fos and DARPP-32 expression that was induced by the DA D2 
antagonist eticlopride in the nucleus accumbens core.  In previous research, DA D2 antagonists 
were shown to increase c-Fos immunoreactivity in striatal regions and that DA D2 antagonism 
activates the cAMP/DARPP-32 signal transduction cascade in medium spiny neurons in the 
striatum that express D2 and A2A receptors (Segovia et al. 2012, Dragunow et al. 1990, Miller, 
1990; Robertson and Fibiger, 1992; Fibiger, 1994; MacGibbon et al., 1994; Wan et al. 1995; 
Pinna et al. 1999, Betz et al. 2009; Farrar et al. 2010, Bonito-Olivia et al. 2011). Other research 
has shown that systemic administration of A2A antagonists can reverse c-Fos expression induced 
by eticlopride, haloperidol, and pimozide which are all DA D2 antagonists (Boegman and 
Vincent, 1996; Pinna et al. 1999; Betz et al. 2009; Farrar et al., 2010). Nucleus accumbens core 
was the area of focus for c-Fos and DARPP-32 expression as previous research has shown that 
nucleus accumbens core is a critical region for D2/ A2A interactions in regulating locomotion and 
effort-related choice behavior (Ishiwari et al. 2007; Font et al. 2008; Farrar et al. 2010; Pardo et 
al. 2012). The immunohistochemistry results suggest that MSX-4 reversed the suppression of 
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locomotion induced by eticlopride due to weakening the cellular effects of D2 antagonism. This 
is consistent with other studies showing that D2 and A2A receptors are colocalized on the same 
medium spiny neurons, and interact via the formation of heteromers onto the same signaling 
pathways (Svenningsson et al. 1999; Ferré et al. 2008; Farrar et al. 2010).  
In summary, MSX-4 induced behavioral and cellular effects that match the profile of an 
adenosine A2A antagonist. Recent research determined that MSX-4 is pharmacologically active 
in vivo and that its prodrug form allows it to be bioavailable. MSX-4 matches the behavioral 
profile of an antiparkinsonian and further suggests the use of adenosine A2A antagonists as a 
therapeutic. Although much of the previous research on adenosine A2A antagonists focuses on 
alleviating symptoms of parkinsonism, these drugs could also be used as treatments of 
motivational symptoms like psychomotor retardation, anergia, and fatigue in depression, 
schizophrenia, and other disorders. 
  
Kovner, R 21 
 
VII. References 
Ahlenius S, Hillegaart V, Thorell G, Magnusson O, Fowler CJ. 1987. Suppression of exploratory 
locomotor activity and increase in dopamine turnover following the local application of 
cis-flupenthixol into limbic projection areas of the rat striatum. Brain Res. 402. 131–8. 
Annett LE, Ridley RM, Gamble SJ, Baker HF. 1989. Social withdrawal following amphetamine 
administration to marmosets. Psychopharmacology. 99. 222–9. 
Antoniou K, Papadopoulou-Daifoti Z, Hyphantis T, Papathanasiou G, Bekris E, Marselos M, et 
al. 2005. A detailed behavioral analysis of the acute motor effects of caffeine in the rat: 
involvement of adenosine A1 and A2A receptors. Psychopharmacology. 183; 154–62. 
Aoyama S, Kase H, Borrelli E. 2000. Rescue of locomotor impairment in dopamine D2 receptor 
deficient mice by an adenosine A2A receptor antagonist. J Neurosci. 20; 5848–52. 
Baldo BA, Kelley AE. 2007. Discrete neurochemical coding of distinguishable motivational 
processes: insights from nucleus accumbens control of feeding. 
Psychopharmacology;191:439–59. 
Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., Morris, M.J., 
Mouradian, M.M., Chase, T.N. 2003. Adenosine A(2A) receptor antagonist treatment of 
Parkinson's disease. Neurology 61, 293-296. 
Barraco, R.A., Martens, K.A., Parizon, M., Normile, H.J. 1993. Adenosine A2a receptors in the 
nucleus accumbens mediate locomotor depression. Brain Res. Bull. 31; 397-404. 
Kovner, R 22 
 
Betz, A.J., Vontell, R., Valenta, J., Worden, L., Sink, K.S., Font, L., Correa, M., Sager, T.N., 
Salamone, J.D. 2009. Effects of the adenosine A2A antagonist KW-6002 (istradefylline) 
on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the 
muscarinic antagonist tropicamide. Neuroscience 163: 97-108. 
Boegman, R.J., Vincent, S.R. 1996. Involvement of adenosine and glutamate receptors in the 
induction of c-fos in the striatum by haloperidol. Synapse 22; 70-77. 
Bonito-Olivia, A., Feyder, M., Fisone, G. 2011 Deciphering the actions of antiparkinsonian and 
antipsyhotic arugs on cAMP/DARPP-32 Signaling. Front. Neuroanat. 5; 38. 
Bruce M.S. The anxiogenic effects of caffeine. 1990. Postgrad Med J 66 Suppl, 2:S18-24. 
Chen, J.F., Moratalla, R., Impagnatiello, F., Grandy, D.K., Cuellar, B., Rubinstein, M., Beilstein, 
M.A., Hacket, E., Fink, J.S., Low, M.J., Ongini, E., Schwarzschild, M.A. 2001. The role 
of the D2 dopamine receptor (D2R) in A2a adenenosine-receptor (A2aR) mediated 
behavioral and cellular responses as revealed by A2a and D2 receptor knockout mice. 
Proc. Natl. Acad. Sci. 98, 1970-1975. 
Collins, L.E., Galtieri, D.J., Collins, P., Jones, S.K., Port, R.G., Paul, N.E., Hockemeyer, J., 
Müller, C.E., Salamone, J.D. 2010a. Interactions between adenosine and dopamine 
receptor antagonists with different selectivity profiles: Effects on locomotor activity. 
Behav. Brain Res. 211, 148-155. 
Collins, L.E., Galtieri, D.J., Brennum, L.T., Sager, T.N., Hockemeyer, J., Müller, C.E., Hinman, 
J.R., Chrobak, J.J., Salamone, J.D. 2010b. Oral tremor induced by the muscarinic agonist 
Kovner, R 23 
 
pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but 
not the adenosine A1 antagonist DPCPX. Pharmacol. Biochem. Behav. 94, 561-569 
 
Collins, L.E., Paul, N.E., Abbas, S.F., Leser, C.E., Podurgiel, S.J., Galtieri, D.J., Chrobak, J.J., 
Baqi, Y., Müller, C.E., Salamone, J.D. 2011. Oral tremor induced by galantamine in rats: 
a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's 
disease. Pharmacol. Biochem. Behav. 99, 414-422. 
 
Collins, L.E., Sager, T.N., Sams, A.G., Pennarola, A., Port, R.G., Shahriari, M., Salamone, J.D. 
2012. The novel adenosine A2A antagonist Lu AA47070 reverses the motor and 
motivational effects produced by dopamine D2 receptor blockade. Pharmacol. 
Biochem.Behav. 100, 498-505. 
Correa M, Carlson BB, Wisniecki A, Salamone JD. Nucleus accumbens dopamine and work 
requirements on interval schedules. Behav Brain Res 2002;137:179–87. 
Correa, M., Font, L. 2008. Is there a major role for adenosine A2A receptors in anxiety? Front. 
Biosci. 13. 4058-4070. 
Correa, M., Wisniecki, A., Betz, A., Dobson, D.R., O'Neill, M.F., O'Neill, M.J., Salamone, J.D. 
2004. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and 
tremulous jaw movements induced by haloperidol in rats: possible relevance to 
parkinsonism. Behav. Brain Res. 148, 47-54. 
Deckert J., Nothen M.M., Franke P., Delmo C., Fritze J., Knapp M., Maier W., Beckmann H. 
and Propping P. 1998. Systematic mutation screening and association study of the A1 and 
Kovner, R 24 
 
A2A adenosine  receptor genes in panic disorder suggest a contribution of the A 2A gene 
to the development of disease Mol Psychiatry 3, 81-85. 
Demyttenaere, K., De Fruyt, J., Stahl, S.M. 2005. The many faces of fatigue in major depressive 
disorder. Int. J. Neuropsychopharmacol. 8, 93-105. 
Dragunow, M., Robertson, G.S., Faull, R.L., Robertson, H.A., Jansen, K. 1990. D2 dopamine 
receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 
37, 287-294. 
Duvauchelle CL, Ikegami A, Asami S, Robens J, Kressin K, Castaneda E. Effects of cocaine 
context on NAcc dopamine and behavioral activity after repeated intravenous cocaine 
administration. Brain Res 2000;862:49–58. 
Davie C.A. A review of Parkinson’s Disease. British medical bulletin. 2008; 86: 109–127 
El Yacoubi, M., Costentin, J., Vaugeois, J.M. 2003. Adenosine A2A receptors and depression. 
Neurology 61, S82-S87. 
El Yacoubi M., Ledent C., Parmentier M., Costentin J. andVaugeois J.M. 2005. Reduced 
appetite for caffeine in adenosine A(2A) receptor knockout mice. Eur J Pharmacol 519, 
290-301. 
El Yacoubi M., Ledent C., Parmentier M., Costentin J.and. Vaugeois J.M. 2000. The anxiogenic-
like effect of caffeine in two experimental procedures measuring anxiety in the mouse is 
not shared by selective A(2A) adenosine receptor antagonists. Psychopharmacology 148, 
153-163. 
Kovner, R 25 
 
Farrar, A.M., Segovia, K.N., Randall, P.A., Nunes, E.J., Collins, L.E., Stopper, C.M., Port, R.G., 
Hockemeyer, J., Müller, C.E., Correa, M., Salamone, J.D. 2010. Nucleus accumbens and 
effort-related functions: behavioral and neural markers of the interactions between 
adenosine A2A and dopamine D2 receptors. Neuroscience 166, 1056-1067. 
Fastbom J., Pazos A., and. Palacios J.M.  1987. The distribution of adenosine A1 receptors and 
5'-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 
22, 813-826.  
Ferré, S. 1997. Adenosine-dopamine interactions in the ventral striatum. Implications for the 
treatment of schizophrenia. Psychopharmacology 133, 107-120. 
Ferré, S., Fredholm, B.B., Morelli, M., Popoli, P., Fuxe, K. 1997. Adenosine-dopamine  
receptorreceptor interactions as an integrative mechanism in the basal ganglia. Trends. 
Neurosci.20, 482-487. 
Ferré, S., Popoli, P., Gimenez-Llort, L., Rimondini, R., Muller, C.E., Stromberg, I., Ogren, S.O., 
Fuxe, K. 2001. Adenosine/dopamine interaction: implications for the treatment of 
Parkinson's disease. Parkinsonism Relat. Disord. 7, 235-241. 
Ferré, S., Ciruela, F., Canals, M., Marcellino, D., Burgueno, J., Casado, V., Hillion, J., Torvinen, 
M., Fanelli, F., Benedetti, P.P., Goldberg, S.R., Bouvier, M., Fuxe, K., Agnati, L.F., 
Lluis, C., Franco, R., Woods, A. 2004. Adenosine A2A-dopamine D2 receptor-receptor 
heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 10, 265- 
271. 
Kovner, R 26 
 
Ferré, S., Quiroz, C., Woods, A.S., Cunha, R., Popoli, P., Ciruela, F., Lluis, C., Franco, R., 
Azdad, K., Schiffmann, S.N. 2008. An update on adenosine A2A-dopamine D2 receptor 
interactions: implications for the function of G protein-coupled receptors. Curr. Pharm. 
Des. 14, 1468-1474 
Fibiger, H.C. 1994. Neuroanatomical targets of neuroleptic drugs as revealed by Fos 
immunochemistry. J. Clin. Psychiat. 55 Suppl B, 33-36. 
Fink, J.S., Weaver, D.R., Rivkees, S.A., Peterfreund, R.A., Pollack, A.E., Adler, E.M., Reppert, 
S.M. 1992. Molecular cloning of the rat A2 adenosine receptor: selective co-expression 
with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 14,186-195. 
Florio C., Prezioso A., Papaioannou A. and Vertua R. Adenosine A1 receptors modulate anxiety 
in CD1 mice. Psychopharmacology  136, 311-319 (1998)  
Font, L., Mingote, S., Farrar, A.M., Pereira, M., Worden, L., Stopper, C., Port, R.G., Salamone, 
J.D. 2008. Intra-accumbens injections of the adenosine A2A agonist CGS 21680 affect 
effort-related choice behavior in rats. Psychopharmacology 199, 515-526. 
Fredholm B.B., Battig K., Holmen J., Nehlig A. and Zvartau E.E. Actions of caffeine in the brain 
with special reference to factors that contribute to its widespread use.1999. Pharmacol 
Rev 51, 83-133. 
Friedman, J.H. 2009. Fatigue in Parkinson's disease patients. Curr. Treat. Options Neurol. 11, 
186-190. 
Fuxe, K., Agnati, L.F., Jacobsen, K., Hillion, J., Canals, M., Torvinen, M., Tinner-Staines, B., 
Staines, W., Rosin, D., Terasmaa, A., Popoli, P., Leo, G., Vergoni, V., Lluis, C., Ciruela, 
Kovner, R 27 
 
F., Franco, R., Ferré, S. 2003. Receptor heteromerization in adenosine A2A receptor 
signaling: relevance for striatal function and Parkinson's disease. Neurology 61, S19-23. 
Fuxe, K., Marcellino, D., Genedani, S., Agnati, L. 2007. Adenosine A(2A) receptors, dopamine 
D(2) receptors and their interactions in Parkinson’s disease. Mov. Disord. 22, 1990-2017. 
Gimenez-Llort L., Fernandez-Teruel A., Escorihuela R.M., Fredholm B.B., Tobena A., Pekny 
M.and Johansson B. Mice lacking the adenosine A1 receptor are anxious and aggressive, 
but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 
16, 547-550 (2002) 
Gong W, Neill DB, Lynn M, Justice JB. Dopamine D1/D2 agonists injected onto nucleus 
accumbens and ventral pallidum differentially affect locomotor activity depending on 
site. Neuroscience 1999;93:1349–58. 
Greden J.F. Anxiety or caffeinism: a diagnostic dilemma. 1974. Am J Psychiatry 131, 1089-
1092. 
Griebel G., Saffroy-Spittler M., Misslin R., Remmy D., Vogel E. and Bourguignon J.J. 
Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 
15943A, and an A1-selective antagonist, DPCPX. 1991. Psychopharmacology 103, 541-
544. 
Hanff, T.C., Furst, S.J., Minor, T.R. 2010. Biochemical and anatomical substrates of depression 
and sickness behavior. Isr. J. Psychiat. Relat. Sci. 47, 64-71. 
Kovner, R 28 
 
Hauber, W., Munkle, M. 1997. Motor depressant effects mediated by dopamine D2 and 
adenosine A2A receptors in the nucleus accumbens and the caudate-putamen. Eur. J. 
Pharmacol. 323, 127-131. 
Hauber, W., Neuscheler, P., Nagel, J., Müller, C.E. 2001. Catalepsy induced by a blockade of 
dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine 
A(2A) receptors in the caudate-putamen of rats. Eur. J. Neurosci. 14,1287-1293. 
Hemby SE, Jones GH, Justice Jr JB, Neill DB. Conditioned locomotor activity but not 
conditioned place preference following intra-accumbens infusions of cocaine. 
Psychopharmacology 1992;106:330–6. 
Hettinger, B.D., Lee, A., Linden, J., Rosin, D.L. 2001. Ultrastructural localization of adenosine 
A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in 
rat striatum. J. Comp. Neurol. 431, 331-346 
Hillion, J., Canals, M., Torvinen, M., Casado, V., Scott, R., Terasmaa, A., Hansson, A., Watson, 
S., Olah, M.E., Mallol, J., Canela, E.I., Zoli, M., Agnati, L.F., Ibanez, C.F., Lluis, C., 
Franco, R., Ferré, S., Fuxe, K. 2002. Coaggregation, cointernalization, and 
codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 
277:18091-18097. 
Hodgson, R.A., Bertorelli, R., Varty, G.B., Lachowicz, J.E., Forlani, A., Fredduzzi, S., Cohen-
Williams, M.E., Higgins, G.A., Impagnatiello, F., Nicolussi, E., Parra, L.E., Foster, C., 
Zhai, Y., Neustadt, B.R., Stamford, A.W., Parker, E.M., Reggiani, A., Hunter, J.C. 2009. 
Characterization of the potent and highly selective A2A receptor antagonists preladenant 
Kovner, R 29 
 
and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-
7Hpyrazolo[ 4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of 
movement disorders and depression. J. Pharmacol. Exp. Ther. 330, 294-303. 
Ishiwari, K., Madson, L.J., Farrar, A.M., Mingote, S.M., Valenta, J.P., DiGianvittorio, M.D., 
Frank, L.E., Correa, M., Hockemeyer, J., Müller, C., Salamone, J.D. 2007. Injections of 
the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core 
attenuate the locomotor suppression induced by haloperidol in rats. Behav. Brain Res. 
178, 190-199. 
Imaizumi M., Miyazaki S. and Onodera K. Effects of xanthine derivatives in a light/dark test in 
mice and the contribution of adenosine receptors. 1994. Methods Find Exp Clin 
Pharmacol, 16, 639-644. 
Jain N., Kemp N., Adeyemo O., Buchanan P. and Stone T.W. Anxiolytic activity of adenosine 
receptor activation in mice.1995. Br J Pharmacol 116, 2127-2133. 
Jegou S., El Yacoubi M., Mounien L., Ledent C., Parmentier M., Costentin J., Vaugeois J.M. and 
Vaudry H. 2003. Adenosine A2A receptor gene disruption provokes marked changes in 
melanocortin content and pro-opiomelanocortin gene expression. J Neuroendocrinol 15, 
1171-1177. 
Johansson B.,. Halldner L, Dunwiddie T.V., Masino S.A., Poelchen W., Gimenez-Llort L., 
Escorihuela R.M., Fernandez-Teruel A., Wiesenfeld-Hallin Z., Xu X.J., Hardemark A., 
Betsholtz C., Herlenius E. and Fredholm B.B.  2001. Hyperalgesia, anxiety, and 
Kovner, R 30 
 
decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl 
Acad Sci U S A 98, 9407-9412. 
Kelley PH, Iversen SD. 1976. Selective 6-OHDA-induced destruction of mesolimbic dopamine 
neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J 
Pharmacol 40:45–56. 
Kelley AE, Gauthier AM, Lang CG. Amphetamine microinjections into distinct striatal 
subregions cause dissociable effects on motor and ingestive behavior. Behav Brain Res 
1989;35:27–39. 
Keppel, G. 1991. Design and Analysis: a researchers handbook. Englewood Cliffs, NJ: Prentice-
Hall. 
Koob GF, Riley SJ, Smith SC, Robbins TW. 1978. Effects of 6-hydroxydopamine lesions of the 
nucleus accumbens septi and olfactory tubercle on feeding, locomotor activity, and 
amphetamine anorexia in the rat. J Comp Physiol Psychol. 92:917–27. 
LeWitt, P.A., Guttman, M., Tetrud, J.W., Tuite, P.J., Mori, A., Chaikin, P., Sussman, N.M. 2008. 
6002-US-005 Study Group. Adenosine A2A receptor antagonist istradefylline (KW- 
6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter 
clinical trial (6002-US-005). Ann. Neurol. 63, 295-302. 
Ledent C., Vaugeois J.M., Schiffmann S.N., Pedrazzini T., El Yacoubi M., Vanderhaeghen J.J.,. 
Costentin J, Heath J.K., Vassart G. and Parmentier M. 1997. Aggressiveness, hypoalgesia 
and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388, 674-
678  
Kovner, R 31 
 
MacGibbon, G.A., Lawlor, P.A., Bravo, R., Dragunow, M. 1994. Clozapine and haloperidol 
produce a differential pattern of immediate early gene expression in rat caudate-putamen, 
nucleus accumbens, lateral septum and islands of Calleja. Brain Res. Mol. Brain Res. 23, 
21-32. 
McCullough LD, Salamone JD. 1992. Involvement of nucleus accumbens dopamine in the motor 
activity induced by periodic food presentation: a microdialysis and behavioral study. 
Brain Res592:29–36. 
Marin, R.S. 1996. Apathy: Concept, Syndrome, Neural Mechanisms, and Treatment. Semin Clin 
Neuropsychiatry 1, 304-314. 
Miller, J.C. 1990. Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. 
JNeurochem 54, 1453-1455. 
Mingote, S., Font, L., Farrar, A.M., Vontell, R., Worden, L.T., Stopper, C.M., Port, R.G., Sink, 
K.S., Bunce, J.G., Chrobak, J.J., Salamone, J.D. 2008. Nucleus accumbens adenosine 
A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway. 
J. Neurosci. 28, 9037-9046. 
Montgomery, K.C. 1958. The relation between fear induced by novel stimulation and 
exploratory behaviour, J. Comp. Physiol. PsychoL, 48: 254-260. 
Morelli, M., Pinna, A. 2001. Interaction between dopamine and adenosine A2A receptors as a 
basis for the treatment of Parkinson's disease. Neurol. Sci. 22, 71-72. 
Moreau J.L. and Huber G. 1999. Central adenosine A(2A) receptors: an overview. Brain Res 
Brain Res Rev 31, 65-82. 
Kovner, R 32 
 
Müller, C.E. 2009. Prodrug approaches for enhancing the bioavailability of drugs with low 
solubility. Chem. Biodivers. 6, 2071-2083. 
Pardo, M., Lopez-Cruz, L., Valverde, O., Ledent, C., Baqi, Y., Müller, C.E., Salamone, J.D., 
Correa, M. 2012. Adenosine A(2A) receptor antagonism and genetic deletion attenuate 
the effects of dopamine D(2) antagonism on effort-based decision making in mice. 
Neuropharmacology 62, 2068-2077. 
Pellegrino, L.J., Pellegrino, A.S., Cushman, A.J. 1979. A stereotaxic atlas of the rat brain. 
Plenum, New York. 
Pinna, A., Wardas, J., Cristalli, G., Morelli, M. 1997. Adenosine A2A receptor agonists increase 
Fos-like immunoreactivity in mesolimbic areas. Brain Res. 759, 41-49. 
Pinna, A., Wardas, J., Cozzolino, A., Morelli, M. 1999. Involvement of adenosine A2A receptors 
in the induction of c-fos expression by clozapine and haloperidol. 
Neuropsychopharmacology 20, 44-51. 
Pinna, A., Wardas, J., Simola, N., Morelli, M. 2005 New therapies for the treatment of 
Parkinson's disease: adenosine A2A receptor antagonists. Life Sci. 77, 3259-3267. 
Pinna, A. 2009. Novel investigational adenosine A2A receptor antagonist for Parkinson’s 
disease. Expert Opin. Investig. Drugs 18, 1619-1631. 
Pinna, A., Tronci, E., Schintu, N., Simola, N., Volpini, R., Pontis, S., Cristalli, G., Morelli, M. 
2010. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and 
biochemical characterization as an antiparkinsonian drug. Neuropharmacology 58, 613- 
623. 
Kovner, R 33 
 
Pijenburg AJ, van Rossum JM. Letter: stimulation of locomotor activity following injection of 
dopamine into the nucleus accumbens. J Pharm Pharmacol 1973;25:1003–5. 
Pijenburg AJ, HonigWM,van der Heyden JA, Van Rossum JM. Effects of chemical stimulation 
of the mesolimbic dopamine system upon locomotor activity. Eur J Pharmacol 
1976;35:45–58. 
Prediger R.D., Batista L.C. and Takahashi R.N. 2004. Adenosine A1 receptors modulate the 
anxiolytic-like effect of ethanol in the elevated plus-maze in mice. Eur J Pharmacol 499, 
147-154. 
Prediger R.D., Da Silva G.E., Batista L.C., Bittencourt A.L. and Takahashi R.N. Activation of 
adenosine A1 receptors reduces anxiety-like behavior during acute ethanol withdrawal 
(hangover) in mice. 2006. Neuropsychopharmacology 31, 2210-20. 
Prut, L., Belzung, C. 2003. The open field as a paradigm to measure the effects of drugs on 
anxiety-like behaviors: A review. Eur. J. Pharmacol. 463, 3-33. 
Qi C, Roseboom PH, Nanda SA, Lane JC, Speers JM, Kalin NH. Anxiety-related behavioral 
inhibition in rats: a model to examine mechanisms underlying the risk to develop stress-
related psychopathology. Genes Brain Behav. 2010 (8):974-84 
Randall, P.A., Nunes, E.J., Janniere, S.L., Stopper, C.M., Farrar, A.M., Sager, T.N., Baqi, Y., 
Hockemeyer, J., Müller, C.E., Salamone, J.D. 2011. Stimulant effects of adenosine 
antagonists on operant behavior: differential actions of selective A2A and A1 antagonists. 
Psychopharmacology 216, 173-186. 
Kovner, R 34 
 
Rautio, J., Kampulainen, H., Heimbach, T., Oliyai, R., Dooman, O., Jarvinen, T., Savolainen, J. 
2008. Prodrugs: design and clinical applications. Nature Reviews 7, 255-270. 
Robertson, G.S., Fibiger, H.C. 1992. Neuroleptics increase c-fos expression in the forebrain: 
contrasting effects of haloperidol and clozapine. Neuroscience 46,315-328. 
Rosin, D.L., Robeva, A., Woodard, R.L., Guyenet, P.G., Linden, J. 1998. Immunohistochemical 
localization of adenosine A2A receptors in the rat central nervous system. J. Comp. 
Neurol. 401, 163-186. 
Salamone, J.D. 2010a. Preladenant, a novel adenosine A(2A) receptor antagonist for the 
potential treatment of parkinsonism and other disorders. IDrugs 13, 723-731. 
Salamone, J.D., Correa, M., Farrar, A., Mingote, S.M. 2007. Effort-related functions of nucleus 
accumbens dopamine and associated forebrain circuits. Psychopharmacology 191, 461-
482. 
Salamone, J.D., Correa, M., Mingote, S.M., Weber, S.M., Farrar, A.M. 2006. Nucleus 
accumbens dopamine and the forebrain circuitry involved in behavioral activation and 
effort-related decision making: implications for understanding anergia and psychomotor 
slowing in depression. Curr. Psychiat. Rev. 2, 267-280. 
Salamone, J.D., Ishiwari, K., Betz, A.J., Farrar, A.M., Mingote, S.M., Font, L., Hockemeyer, J., 
Müller, C.E., Correa, M. 2008a. Dopamine/adenosine interactions related to locomotion 
and tremor in animal models: possible relevance to parkinsonism. Parkinsonism Relat. 
Disord. 14 Suppl 2, S130-134. 
Kovner, R 35 
 
Salamone, J.D., Betz, A.J., Ishiwari, K., Felsted, J., Madson, L., Mirante, B., Clark, K., Font, L., 
Korbey, S., Sager, T.N., Hockemeyer, J., Müller, C.E. 2008b. Tremorolytic effects of 
adenosine A2A antagonists: implications for parkinsonism. Front. Biosci. 13, 3594-3605. 
Salamone, J.D., Correa, M., Farrar, A.M., Nunes, E.J., Collins, L.E. 2010. The role of dopamine/ 
adenosine interactions in the brain circuitry regulating effort-related decision making: 
Insights into pathological aspects of motivation. Fut. Neurol. 5, 377-392. 
Santerre, J., Nunes, E.J., Kovner R., Leser, C.,  Randall P.A., Collins-Praino L.E., Lopez-Cruz, 
L., Correa, M., Baqi, Y., Muller, C.E., Salamone, J.D. .Submitted. The novel adenosine 
A2A antagonist pro-drug MSX-4 is effective in animal models related to motivational 
and motor function. Neuropsychopharm. 
Schiffmann, S.N., Jacobs, O., Vanderhaeghen, J.J. 1991. Striatal restricted adenosine A2 receptor 
(RDC8) is expressed by enkephalin but not by substance P neurons: an in situ 
hybridization histochemistry study. J. Neurochem. 57, 1062-1067. 
Segovia, K.N., Correa, M., Salamone, J.D. 2012. Changes in nucleus accumbens and neostriatal 
c-Fos and DARPP-32 immunoreactivity during different stages of food-reinforced 
instrumental training. Eur. J. Neurosci. in press 
Simola, N., Fenu, S., Baraldi, P.G., Tabrizi, M.A., Morelli, M. 2004. Blockade of adenosine 
A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on 
specific striatal regions. Exp. Neurol. 189, 182-188. 
Kovner, R 36 
 
Simola, N., Fenu, S., Baraldi, P.G., Tabrizi, M.A., Morelli, M. 2006. Dopamine and adenosine 
receptor interaction as basis for the treatment of Parkinson's disease. J. Neurol. Sci. 248, 
48-52. 
Sink, K.S., Vemuri, V.K., Olszewska, T., Makriyannis, A., Salamone, J.D. 2008. Cannabinoid 
CB1 antagonists and dopamine antagonists produce different effects on a task involving 
response allocation and effort-related choice in food-seeking behavior. 
Psychopharmacology 196, 565-574. 
Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine 
A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by 
reserpine or MPTP. Psychopharmacology 1999;147:90–5. 
Stromberg, I., Popoli, P., Müller, C.E., Ferré, S., Fuxe, K. 2000. Electrophysiological and 
behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in 
dopamine D2 receptor regulation in dopamine-denervated striatum. Eur. J. Neurosci. 12, 
4033-4037. 
Svenningsson, P., Le Moine, C., Fisone, G., Fredholm, B.B. 1999. Distribution, biochemistry 
and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59, 355-396. 
Thorsell A., Johnson J. and Heilig M.. Effect Of The Adenosine A2A Receptor Antagonist 3,7-
Dimethyl-Propargylxanthine On Anxiety-Like And Depression-Like Behavior And 
Alcohol Consumption In Wistar Rats. Alcohol Clin Exp Res 31, 1302-1307 (2007)  
Kovner, R 37 
 
Tronci, E., Simola, N., Borsini, F., Schintu, N., Frau, L., Carminati, P., Morelli, M. 2007. 
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor 
antagonist ST1535: acute and subchronic studies in rats. Eur. J. Pharmacol. 566, 94-102. 
Uhde T.W., Boulenger J.P., Jimerson D.C. and Post R.M. 1984. Caffeine: relationship to human 
anxiety, plasma MHPG and cortisol. Psychopharmacol Bull 20, 426-430. 
Vollmann, K., Qurishi, R., Hockemeyer, J., Müller, C.E. 2008. Synthesis and properties of a new 
water soluble prodrug of the adenosine A 2A receptor antagonist MSX-2. Molecules 13, 
348-359. 
Wan, W., Ennulat, D.J., Cohen, B.M. 1995. Acute administration of typical and atypical 
antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. 
Brain Res. 688, 95-104. 
Wang, W.F., Ishiwata, K., Nonaka, H., Ishii, S., Kiyosawa, M., Shimada, J., Suzuki, F., Senda, 
M. 2000. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS 
adenosine A(2A) receptors with positron emission tomography. Nucl. Med. Biol. 27, 
541-546. 
Wardas, J., Konieczny, J., Lorenc-Koci, E. 2001. SCH 58261, an A(2A) adenosine receptor 
antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41,160-171. 
Worden, L.T., Shahriari, M., Farrar, A.M., Sink, K.S., Hockemeyer, J., Müller, C.E., Salamone, 
J.D. 2009. The adenosine A2A antagonist MSX-3 reverses the effort-related effects of 
dopamine blockade: differential interaction with D1 and D2 family antagonists. 
Psychopharmacology 203, 489-499. 
Kovner, R 38 
 
VII. Figure Captions 
Figure 1. Total locomotor activity counts measured in the open field arena. Rats received IP 
injections of vehicle plus vehicle (Veh/Veh), 0.08 mg/kg eticlopride plus vehicle (Etic/Veh), 
0.08 mg/kg eticlopride plus 8.0 mg/kg MSX-4, or vehicle plus 8.0 mg/kg MSX-4. # eticlopride 
plus vehicle significantly differed from vehicle/vehicle, p<0.05; * significantly different from 
eticlopride plus vehicle p < 0.05. 
 
Figure 2. Relative inner activity measured in the open field arena ((inner counts/total counts)* 
100). Rats received IP injections of vehicle plus vehicle (Veh/Veh), 0.08 mg/kg eticlopride plus 
vehicle (Etic/Veh), 0.08 mg/kg eticlopride plus 8.0 mg/kg MSX-4, or vehicle plus 8.0 mg/kg 
MSX-4.  
 
Figure 3. Results of the c-Fos immunohistochemistry. Rats received IP injections of vehicle plus 
vehicle (Veh/Veh), 0.08 mg/kg eticlopride plus vehicle (Etic/Veh), 0.08 mg/kg eticlopride plus 
8.0 mg/kg MSX-4, or vehicle plus 8.0 mg/kg MSX-4. A. Representative schematics showing 
regions of interest for photomicrographs in the nucleus accumbens core (for clarity, regions are 
marked on only one side of the brain; Figure is modified from Paxinos and Watson, 1998). B. 
Photomicographs from representative rats, showing c-Fos expression in nucleus accumbens core 
across each drug treatment condition. C. Quantification of number of c-Fos positive cells in the 
accumbens core across the different treatment conditions. # eticlopride plus vehicle significantly 
differed from vehicle/vehicle, p<0.05; * significantly different from eticlopride plus vehicle p < 
0.05. 
 
Figure 4. Results of the DARPP-32 immunohistochemistry. Rats received IP injections of 
vehicle plus vehicle (Veh/Veh), 0.08 mg/kg eticlopride plus vehicle (Etic/Veh), 0.08 mg/kg 
eticlopride plus 8.0 mg/kg MSX-4, or vehicle plus 8.0 mg/kg MSX-4. A. Representative 
schematics showing regions of interest for photomicrographs in the nucleus accumbens core (for 
clarity, regions are marked on only one side of the brain; Figure is modified from Paxinos and 
Watson, 1998). B. Photomicographs from representative rats, showing DARPP-32 expression in 
nucleus accumbens core across each drug treatment condition. C. Quantification of number of 
DARPP-32 positive cells in the accumbens core across the different treatment conditions. # 
eticlopride plus vehicle significantly differed from vehicle/vehicle, p<0.05; * significantly 
different from eticlopride plus vehicle p < 0.05. 
 
Figure 5. The open field consisted of a Plexiglas-covered black floor  (115×115 cm) with red 
lines spaced 23 cm apart, dividing the floor into a five-by-five grid. Walls around the perimeter 
measured 44 cm in height. Testing was performed in a very dimly lit room with a single red light 
situated above the center of the box (not shown here).   
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VII. Figures 
Figure 1. Open field total locomotor activity 
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Figure 2. Open field anxiety index 
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Figure 3. c-Fos immunohistochemistry 
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Figure 4. pDARPP32-THR34 immunohistochemistry  
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Figure 5.Example of the open field arena. 
 
 
